Cargando…

489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns

BACKGROUND: Elizabethkingia spp. is a non-fermenting, non-motile, oxidase-positive gram-negative aerobic bacilli that is ubiquitous in the environment, found in freshwater, saltwater and soil. Nowadays, they are emerging as nosocomial pathogens. In this study, we analyzed Elizabethkingia spp infecte...

Descripción completa

Detalles Bibliográficos
Autores principales: Seong, Hye, Ho Kim, Jung, Choi, Heun, young Ahn, Jin, su Ku, Nam, yong Choi, Jun, Yeom, Joon-Sup, Myung Kim, June, Jin Jeong, Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808952/
http://dx.doi.org/10.1093/ofid/ofz360.2508
_version_ 1783461863255703552
author Seong, Hye
Ho Kim, Jung
Choi, Heun
young Ahn, Jin
su Ku, Nam
yong Choi, Jun
Yeom, Joon-Sup
Myung Kim, June
Jin Jeong, Su
author_facet Seong, Hye
Ho Kim, Jung
Choi, Heun
young Ahn, Jin
su Ku, Nam
yong Choi, Jun
Yeom, Joon-Sup
Myung Kim, June
Jin Jeong, Su
author_sort Seong, Hye
collection PubMed
description BACKGROUND: Elizabethkingia spp. is a non-fermenting, non-motile, oxidase-positive gram-negative aerobic bacilli that is ubiquitous in the environment, found in freshwater, saltwater and soil. Nowadays, they are emerging as nosocomial pathogens. In this study, we analyzed Elizabethkingia spp infected cases clinically and microbiologically. METHODS: This study was performed to evaluate the risk factors for mortality and to study the impact of microbiologic response on clinical outcomes in patient with Elizabethkingia spp Data on 210 patient of Elizabethkingia pneumonia and bacteremia that have occurred between November 1, 2005, and May 31, 2016, in a teaching hospital (2000 beds) in Seoul, Korea, were analyzed. Furthermore, antimicrobial susceptibility testing of Elizabethkingia from sputum and blood cultures was performed by E test for rifampin, moxifloxacin and vancomycin. RESULTS: Among 210 patients, there were 157(74.8%) survivor and 53(25.2%) non-survivor. Among these patients, 129 patients (61.4%) were male and the median age was 66.5 years. There were no significant differences in the Charlson comorbidity index between survivor and non-survivor groups (P = 0.413). In the multivariate logistic regression, microbiologic failure (odds ratio [OR], 7.862; 95% confidence interval [CI], 3.448–17.931; pElizabethkingia infection (OR, 1.032; 95% CI, 1.013–1.051; P = 0.001), previous use of immunosuppressants (OR, 3.309; 95% CI, 1.334–8.210; P = 0.010), and Percutaneous cardiopulmonary support system use at the time of Elizabethkingia infection (OR, 7.439; 95% CI,1.180–46.900; P = 0.033) were significantly associated with 28day mortality. Patients with moxifloxacin-resistant and vancomycin-resistant showed higher mortality rate but no statistically significant difference. CONCLUSION: The early identification of these clinical factors in patients with Elizabethkingia infection is important to improve prognosis DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6808952
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68089522019-10-28 489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns Seong, Hye Ho Kim, Jung Choi, Heun young Ahn, Jin su Ku, Nam yong Choi, Jun Yeom, Joon-Sup Myung Kim, June Jin Jeong, Su Open Forum Infect Dis Abstracts BACKGROUND: Elizabethkingia spp. is a non-fermenting, non-motile, oxidase-positive gram-negative aerobic bacilli that is ubiquitous in the environment, found in freshwater, saltwater and soil. Nowadays, they are emerging as nosocomial pathogens. In this study, we analyzed Elizabethkingia spp infected cases clinically and microbiologically. METHODS: This study was performed to evaluate the risk factors for mortality and to study the impact of microbiologic response on clinical outcomes in patient with Elizabethkingia spp Data on 210 patient of Elizabethkingia pneumonia and bacteremia that have occurred between November 1, 2005, and May 31, 2016, in a teaching hospital (2000 beds) in Seoul, Korea, were analyzed. Furthermore, antimicrobial susceptibility testing of Elizabethkingia from sputum and blood cultures was performed by E test for rifampin, moxifloxacin and vancomycin. RESULTS: Among 210 patients, there were 157(74.8%) survivor and 53(25.2%) non-survivor. Among these patients, 129 patients (61.4%) were male and the median age was 66.5 years. There were no significant differences in the Charlson comorbidity index between survivor and non-survivor groups (P = 0.413). In the multivariate logistic regression, microbiologic failure (odds ratio [OR], 7.862; 95% confidence interval [CI], 3.448–17.931; pElizabethkingia infection (OR, 1.032; 95% CI, 1.013–1.051; P = 0.001), previous use of immunosuppressants (OR, 3.309; 95% CI, 1.334–8.210; P = 0.010), and Percutaneous cardiopulmonary support system use at the time of Elizabethkingia infection (OR, 7.439; 95% CI,1.180–46.900; P = 0.033) were significantly associated with 28day mortality. Patients with moxifloxacin-resistant and vancomycin-resistant showed higher mortality rate but no statistically significant difference. CONCLUSION: The early identification of these clinical factors in patients with Elizabethkingia infection is important to improve prognosis DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6808952/ http://dx.doi.org/10.1093/ofid/ofz360.2508 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Seong, Hye
Ho Kim, Jung
Choi, Heun
young Ahn, Jin
su Ku, Nam
yong Choi, Jun
Yeom, Joon-Sup
Myung Kim, June
Jin Jeong, Su
489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns
title 489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns
title_full 489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns
title_fullStr 489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns
title_full_unstemmed 489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns
title_short 489. Risk Factors for Mortality in Patients with Elizabethkingia and Clinical Impact of Antimicrobial Susceptibility Patterns
title_sort 489. risk factors for mortality in patients with elizabethkingia and clinical impact of antimicrobial susceptibility patterns
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808952/
http://dx.doi.org/10.1093/ofid/ofz360.2508
work_keys_str_mv AT seonghye 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT hokimjung 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT choiheun 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT youngahnjin 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT sukunam 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT yongchoijun 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT yeomjoonsup 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT myungkimjune 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns
AT jinjeongsu 489riskfactorsformortalityinpatientswithelizabethkingiaandclinicalimpactofantimicrobialsusceptibilitypatterns